Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Summary

To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Timeline

Start

2010-04

Primary completion

2012-03

Completion

2013-03

Publications

• Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer. 2013 Sep 17;109(6):1414-9. doi: 10.1038/bjc.2013.470. Epub 2013 Aug 29.

Drugs

Indications